Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01036958
Other study ID # 100019
Secondary ID 10-C-0019
Status Completed
Phase
First received
Last updated
Start date November 25, 2009
Est. completion date February 6, 2018

Study information

Verified date February 6, 2018
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- Chronic graft-vs-host disease (GVHD) is an important cause of morbidity and mortality in patients undergoing allogeneic bone marrow transplantation. The symptoms of chronic GVHD are similar to those of other autoimmune diseases, and treatment for the pain often involves steroid use that can cause severe side effects over the long term.

- At present, there is no research instrument that measures symptoms in children with chronic GVHD. Treatment practitioners may use one of several pediatric quality of life questionnaires, but because none of these is specific for chronic GVHD each instrument has potential gaps in its ability to assess the full spectrum of problems experienced by children with chronic GVHD. Researchers are interested in developing a better understanding of the disease burden experienced by children and adolescents with chronic GVHD.

Objectives:

- To develop a Pediatric Chronic GVHD Symptom Scale (PCSS) that reliably measures the disease-specific burden of chronic GVHD in children.

Eligibility:

- Children and adolescents 5 to 18 years of age who have undergone prior allogeneic stem cell transplant and have been diagnosed with chronic GVHD that requires treatment.

Design:

- There are two phases to the study; participants will enroll in phase I (question generation) at this time.

- Researchers will interview participants and ask open-ended questions (requiring more than a one- or two-word response) about symptoms that adults with chronic GVHD have found problematic.

- Both parents and children will participate in the interviews, which will be audio-recorded. Depending on the child or adolescent s age, the interviews may be conducted together with the parents or separately.

- No treatment will be given as part of this study.


Description:

Background:

- Currently, a large number of children with chronic GVHD have to deal with many years of a disfiguring and painful chronic illness with the side effects of long term steroid use.

- The broad categories of limited and extensive chronic GVHD are recognized by clinicians, but are not particularly useful in clinical practice. Chronic GVHD may involve almost every organ although it most commonly affects skin, eyes, mouth, liver, intestines, lung and musculoskeletal system.

- Recently, there has been a large effort through the NIH Consensus for chronic GVHD to standardize response criteria for patients with chronic GVHD, on clinical trials. Because of the absence of evidence suggesting which response criteria truly correlates with improvement, the NIH Consensus Panel has recommended following not only physical signs of chronic GVHD, but also symptoms of GVHD.

Primary Objective:

- Develop a Pediatric Chronic GVHD Symptom Scale (PCSS) that reliably measures the disease specific burden of chronic GVHD in children.

Secondary Objectives:

- Correlate high and low scores on the PCSS with standard quality of life measures.

- Determine using the Rasch measurement model whether the PCSS has sufficient sensitivity to change for the scale to be useful in clinical intervention trials.

Eligibility:

- Children of 5 to 18 years of age, who have undergone prior allogeneic stem cell transplant

- Clinical diagnosis of chronic GVHD with need for systemic treatment

- No evidence of primary disease relapse

- Must be willing to sign informed consent, or if applicable, child assent

Design:

- With the final goal of developing a scale that is similar in design to the Lee Scale but which measures the symptom burden more specifically for children with chronic GVHD, the study will be conducted in two phases: item generation and psychometric validation.

- In phase I, the local team at each institution will interview participants using a script to identify symptom concerns for pediatric chronic GVHD patients. Based on interviews, we will decide whether to test different scales for the different age groups, or a single scale for all.

- Data from Phase II will be used to finalize and validate the pediatric symptom scale, through the assessment of test-retest characteristics, use of item reduction, examination of construct validity, internal consistency, convergent and divergent validity, and evaluation of sensitivity to change.


Recruitment information / eligibility

Status Completed
Enrollment 3
Est. completion date February 6, 2018
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 5 Years to 18 Years
Eligibility - INCLUSION CRITERIA:

- Children of 5 to 18 years of age, who have undergone prior allogeneic stem cell transplant.

- Clinical diagnosis of chronic GVHD with need for systemic treatment.

- No evidence of primary disease relapse.

- Must be willing to sign informed consent, or if applicable, child assent.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Champlin RE, Gale RP. The early complications of bone marrow transplantation. Semin Hematol. 1984 Apr;21(2):101-8. Review. — View Citation

Sullivan KM, Parkman R. The pathophysiology and treatment of graft-versus-host disease. Clin Haematol. 1983 Oct;12(3):775-89. Review. — View Citation

Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE, Lerner KG, Glucksberg H, Buckner CD. Bone-marrow transplantation (first of two parts). N Engl J Med. 1975 Apr 17;292(16):832-43. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Develop pediatric cGVHD symptom scale 24 months
Secondary Rasch measurement model, determine sensitivity to use in clinicalintervention trials 24 months
Secondary Correlate scores with QOL measures 24 months
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04189432 - Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT03557749 - Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies
Completed NCT05121142 - Study of Ruxolitinib for Acute and Chronic Graft Versus Host Disease Phase 1
Recruiting NCT04202835 - ATG Plus PTCy vs ATG for CGVHD Prophylaxis Phase 2
Terminated NCT03640481 - Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy Phase 2
Recruiting NCT04372524 - Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PTCTC GVH 1901 Study
Active, not recruiting NCT03604692 - A Phase 1/2 Study to Evaluate SNDX- 6352 in Participants With Active cGVHD Phase 1/Phase 2
Recruiting NCT05355675 - The Association of Microbiota Composition With cGVHD After Allo-HSCT
Active, not recruiting NCT04710576 - A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) Phase 2
Terminated NCT04200365 - A Study of Itacitinib for the Treatment of Chronic Graft Versus Host Disease (cGVHD) Phase 2
Not yet recruiting NCT06263478 - A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Axatilimab Monotherapy in Japanese Participants With Recurrent or Refractory Active Chronic Graft-Versus-Host Disease Phase 3
Not yet recruiting NCT06388564 - A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease Phase 2
Terminated NCT02123966 - An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease Phase 2
Recruiting NCT05692713 - Polyomic Biomarker Verification in Adult Chronic Graft-Versus-Host Disease (ABLE3.0/CTTC2201)
Terminated NCT04446182 - Itacitinib (INCB039110) and Extracorporeal Photopheresis (ECP) for First-Line Treatment in Chronic GVHD Phase 2
Active, not recruiting NCT05305989 - Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213 Phase 2
Active, not recruiting NCT02340676 - A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD Phase 2
Completed NCT04540133 - Dexamethasone Solution and Dexamethasone in Mucolox™ Phase 2
Not yet recruiting NCT03190733 - A Optimal Anti-Thymoglobuline (ATG) Dose Decrease cGVHD But Not Increase Leukemia Relapse for Haplo-HSCT Phase 4
Active, not recruiting NCT04716075 - Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Phase 2